NewswireToday - /newswire/ -
London, United Kingdom, 2007/07/27 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report showing the growth of MS treatments from $4.4 billion in 2004 to nearly $5.9 billion in 2006.
“Multiple Sclerosis: Worldwide Market Outlook to 2011” predicts a growth of $6 million by 2011. The report shows the approval of four MS treatment therapies, which generated more than $1 billion in sales each in 2006, contributed to the market’s 15% increase over 2004.
The report predicts that new formulations for existing treatments and new developments, as well as the rising rate of MS across several regions of the world, will support a 15.2% revenue increase over the next five years.
An estimated 2.5 million people worldwide suffer from MS which is a chronic disease that causes significant disability, inflammation, and scarring of the myelin sheaths covering nerves.
A decision by the National Institute for Health and Clinical Excellence (NICE) to recommend Tysabri (natalizumab) for a severe form of multiple sclerosis (MS) offers UK patients renewed hope of regaining control over their disease.
NICE’s recommended the new MS drug Tysabri for use in patients with rapidly evolving severe relapse-remitting MS. With no other disease modifying drug recommended by NICE for MS, this recommendation represents a significant milestone for the UK MS market, although it is understood that this will have no impact on the ongoing risk-sharing scheme for other treatments.
The rapid, sustained uptake of Tysabri will result in it becoming the UK MS market leader by 2009, with sales of $29m. With the ongoing restrictions to other marketed drugs and Tysabri’s impressive efficacy profile, this market-leading status is forecast to continue through to 2016.
Tysabri is the first treatment to be specifically licensed for RES RRMS. Over a two year period, treatment with Tysabri has been shown to result in a 68% relative reduction in clinical relapses and a 54% relative reduction in the risk of sustained disability progression compared with placebo. Subsequently MS sufferers will be able to enjoy a more active and less dependable life.
The report concludes that the disease is undergoing dramatic changes. Regions that were once considered to have low incidence and prevalence of multiple sclerosis are now displaying increases that were not apparent even within the last 10 years.
“Multiple Sclerosis: Worldwide Market Outlook to 2011” focuses on currently marketed products in the MS market and includes statistical information for MS worldwide and by selected countries, with special emphasis on the major pharmaceutical markets: the United States, Europe, and Japan.
The report also analyzes new treatments in the pipeline, triggers and risk factors, leading competitors, and current issues and trends affecting the industry.
“Multiple Sclerosis: Worldwide Market Outlook to 2011”is available from Report Buyer. For more information, please visit the website.
Report Buyer product ID: KAL00026
About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 28,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.